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AbstrACt 
Objective To investigate relationships between maternal 
smoking status in pregnancy and infant development. The 
largest randomised controlled trial of nicotine replacement 
therapy (NRT) for smoking cessation in pregnancy, the smoking, 
nicotine and pregnancy (SNAP) trial, found that at 1 month 
after randomisation, smoking cessation rates were doubled in 
the NRT group compared with the placebo group. At delivery, 
there was no significant difference in cessation rates between 
groups. Surprisingly, infants born to women randomised to NRT 
were more likely to have unimpaired development at 2 years. 
We hypothesised that this apparently protective effect was due 
to smoking cessation caused by NRT and so, investigate this 
relationship using the same cohort.
Design Secondary analysis of a randomised controlled trial.
setting Seven antenatal hospitals in the Midlands and North-
West England.
Participants Eight hundred and eighty-four pregnant smokers 
randomised to receive either NRT patches or visually-identical 
placebo in the SNAP trial. Participants’ smoking behaviour were 
recorded at randomisation, 1 month after their target quit date 
and at delivery.
Methods Using logistic regression models, we investigated 
associations between participants’ smoking measures and 
infant development (assessed using the Ages and Stages 
questionnaire) at 2 years.
Main outcome measures 2 year infant development.
results Developmental impairment was reported for 
12.7% of study 2 year olds. Maternal heaviness of smoking 
at randomisation (OR: 1.26, 95% CI: 0.82 to 1.96, p=0.091), 
validated smoking abstinence recorded at 1 month after a quit 
date (OR: 1.02, 95% CI: 0.60 to 1.74, p=0.914) and validated 
smoking abstinence recorded at both 1 month after a quit 
date and at the end of pregnancy (OR: 1.52, 95% CI: 0.81 to 
2.85, p=0.795) were not independently associated with infant 
developmental impairment at 2 years.
Conclusion We found no evidence that NRT treatment 
improved infants' developmental outcomes through smoking 
cessation.
trial registration number CTA03057/0002/001-0001; 
Post-results 
IntrODuCtIOn
Smoking in pregnancy is associated with 
increased risks of many adverse outcomes 
including miscarriage, stillbirth, prematu-
rity, low birth weight, perinatal morbidity 
and mortality1 and is a substantial interna-
tional public health problem; in high income 
countries 13% to 25% of pregnant women 
smoke2–5 and in developing countries,6 7 the 
WHO predicts a future epidemic. Fortu-
nately, impacts on the foetus are avoidable 
and cessation in pregnancy improves infants’ 
birth weights and reduces the risk of prema-
ture birth.8 Additionally, pregnancy is the life 
event which seems to most motivate smokers’ 
cessation attempts; over 50% of UK pregnant 
smokers try stopping.5 Women are, there-
fore, likely to be receptive to support with 
stopping and, as it is effective for non-preg-
nant smokers9 and possibly also for pregnant 
smokers too, nicotine replacement therapy 
strengths and limitations of this study
 ► This study uses data from the smoking, nicotine 
and pregnancy (SNAP) trial, the largest randomised 
controlled trial of nicotine replacement therapy for 
smoking cessation in pregnancy.
 ► The SNAP trial remains the only maternal smoking 
cessation trial to investigate infant outcomes be-
yond delivery.
 ► Baseline characteristics and potential confounders 
were included in multivariable analyses to deter-
mine independent associations between maternal 
smoking and 2 year developmental outcomes.
 ► Maternal factors which were not measured in the 
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(NRT) is frequently offered to pregnant women who 
smoke.10 Although NRT is not thought to be completely 
risk-free because it exposes users to nicotine, this is 
considered safer than smoking because smokers are 
already nicotine-exposed and NRT users are not exposed 
to the numerous harmful chemicals and tobacco smoke 
carcinogens such as carbon monoxide, tar and lead.
Animal experiments and human-subject laboratory 
investigations suggest that nicotine may adversely affect 
the foetal cardiovascular system and developing nerve 
tissue,11 12 however trials of NRT for smoking cessation in 
pregnancy have been permitted because any foetal harm 
from the nicotine would likely be compensated for by the 
benefits of mothers stopping smoking.13 In the largest of 
these trials, compliance rates in both the NRT and the 
placebo arms were low, with only 7.2% of women assigned 
to receive NRT and 2.8% of women assigned to receive 
placebo, using patches for more than 1 month. Nicotine 
patches doubled cessation rates at 4 weeks but by delivery 
there was no significant difference in cessation rates 
between the NRT and placebo groups.14 Unexpectedly, 
infants born to NRT group women were 40% more likely 
to have unimpaired development at 2 years of age than 
infants born to women in the placebo groups15 (OR: 1.40, 
95% CI: 1.05 to 1.86, p=0.023) and there was a dose-re-
sponse relationship between adherence to NRT and 
impairment-free infant development.15 It seems implau-
sible that this effect would be due to nicotine having a 
direct beneficial effect on the foetus, and there is a possi-
bility that the observed effect might be due to differences 
in unmeasured characteristics between the participants in 
the NRT group and those in the placebo group. However, 
as NRT had a substantial impact on cessation in early 
pregnancy, we hypothesise that the better developmental 
outcomes in NRT group infants and the dose-response 
relationship between increasing NRT use and these might 
be explained by smoking cessation during pregnancy 
caused by NRT use. Consequently, we present secondary 
analyses of data from the same trial to investigate whether 
the absence of infants’ developmental impairments 
at 2 years was associated with maternal smoking status 
measured at different points in the trial.
MethODs
study participants
We used data from the smoking, nicotine and pregnancy 
(SNAP) trial, a placebo randomised-controlled trial of 
NRT for smoking cessation in pregnant women.14 The 
trial recruited 1050 participants aged 16 to 45 years 
between 12 and 24 weeks gestation who smoked at least 
10 cigarettes a day before pregnancy and at least five 
cigarettes a day during pregnancy, with exhaled carbon 
monoxide (CO) readings of ≥8 ppm. Participants were 
randomised to receive up to an 8 week course of either 
15 mg per 16 hours of NRT patches or visually-identical 
placebo. For safety reasons, women were instructed that 
if they smoked at all while using patches, the NRT should 
be stopped. Participants set a target quit date and were 
followed up 1 month after this, during hospital admission 
for delivery or as soon as possible afterwards and at 24 
months after delivery.
Maternal baseline data and smoking behaviour measures
Baseline data included maternal date of birth, age on 
leaving full-time education, number of cigarettes smoked 
per day prior to and during pregnancy, Body Mass Index 
(BMI), the Heaviness of Smoking Index (HSI) - a measure 
of nicotine dependence which is a six-point scale derived 
from the time to first cigarette after waking and the 
number of cigarettes smoked daily.16 Other data included 
were previous use of NRT in the current pregnancy and 
partners’ smoking status.
Self-reported smoking data were obtained 1 month 
after the target quit date and at delivery. Self-reported 
smoking abstinence at 1 month after the quit date was 
validated by exhaled CO measurements below 8 ppm 
while abstinence at delivery was validated by CO measure-
ments and saliva cotinine concentrations below 10 ng/
mL. Carbon monoxide is exhaled from the breath after 
smoking cigarettes and was used to confirm abstinence 
within the preceding 24 hours. Salivary cotinine on the 
other hand was used to determine smoking exposure 
within the last 7 days.17 No data on tobacco smoke expo-
sure were collected between the 1 month follow-up date 
and delivery. Self-reported data on the use of nicotine 
patches were collected 1 month after the target quit date 
and at delivery; adherence to NRT have been reported 
elsewhere.14
Infant outcome measures
Birth status (live or stillbirth), gestational age at birth, 
birth weight, singleton or multiple birth, sex and gesta-
tional age at birth were recorded at delivery and have 
been reported elsewhere.14 The presence of infant devel-
opmental impairment at 24 months was determined 
using questionnaire responses from participants or from 
healthcare professionals when there was no participant 
response; full details have been described previously.15 
Participants reported on their infants’ development as 
assessed within the five domains of the Ages and Stages 
Questionnaire, Third Edition (ASQ-3): communication, 
gross motor, fine motor, problem solving and person-
al-social skills.15 Participant questionnaires (PQ2) were 
posted out at 24 months and if no response was received, 
health professional ones were dispatched to non-re-
spondents’ family physicians. Health professional ques-
tionnaire (HPQ) items were consistent with domains 
in participant questionnaires and were designed to be 
completed with reference to medical or health visitor 
records. Health professionals completing these question-
naires required relatively little knowledge of the patient. 
However if they were unable to complete the question-
naire, they were asked to forward these to children’s’ 
health visitors.18 Scores from the five ASQ-3 domains and 
responses to ‘non-domain’ ASQ-3 items in the participant 
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questionnaires were used with established norms to cate-
gorise infants as having ‘developmental impairment’ or 
‘no developmental impairment’. Infants with only HPQ 
responses were considered to have no developmental 
impairment when the responses from all questions indi-
cated no potential developmental issues.15 As shown in 
the main study, 88% of study participants returned a PQ2 
or HPQ. The proportion of participants assessed using 
the PQ2 or HPQ were similar in the treatment arm and 
placebo arm. Approximately two-thirds of participants 
completed and returned the PQ2, while the HPQ was the 
source of data for children of the remaining participants.
Measures of tobacco smoke exposure
As outlined above, smoking behaviour measures were 
collected at randomisation, 1 month after a target quit 
date and at the end of pregnancy. From these data, we 
derived the following categories to represent different 
levels of tobacco smoke exposure during pregnancy: (i) 
Number of cigarettes smoked daily during pregnancy, 
at randomisation, (ii) HSI at randomisation, catego-
rised as high (4 to 6) or low (0 to 3), (iii) Women who 
reported not smoking between their target quit date and 
1 month, validated using exhaled CO and (iv) Women 
who reported not smoking between their target quit date 
and the end of pregnancy or shortly afterwards, validated 
by either or both of exhaled CO and saliva cotinine at 
the end of pregnancy and also by exhaled CO at 1 month 
after their quit date.
As all trial participants smoked at the time of randomi-
sation, exposure category (ii) was intended to dichoto-
mise those who smoked more heavily and less heavily in 
the first weeks of pregnancy prior to study randomisation. 
For categories (iii) and (iv), we hypothesised that those 
demonstrating validated abstinence at both 1 month and 
the end of pregnancy (category iv) would have a lower 
overall tobacco smoke exposure than those for whom 
abstinence was only validated at 1 month after their quit 
date. However, it should be noted that no biochemical 
test can validate smoking cessation for a prolonged period 
and some women in either group may have smoked for a 
time between baseline/study enrolment and 1 month or 
the end of pregnancy.
Analyses
Maternal and infant characteristics were analysed by 
study arm, for participants who had singleton live births 
and 2 year data on infant developmental impairment. 
Summary statistics were represented as number (%), 
mean (SD) and median (IQR) for categorical, normal 
continuous and non-normal continuous variables, respec-
tively. Univariable logistic regression investigated the 
association between 2 year developmental outcomes and 
different measures of maternal tobacco smoke exposure 
such as baseline number of cigarettes smoked daily in 
pregnancy, the heaviness of smoking index during preg-
nancy, maternal smoking abstinence at some point during 
pregnancy (measured 1 month after the participants’ 
set quit date) and maternal smoking abstinence during 
the latter stages of pregnancy (measured at delivery). In 
multivariable analyses, we adjusted the univariate models 
for baseline characteristic variables and also controlled 
for variables that could confound the association between 
maternal smoking and infant developmental impairment. 
Potential confounders included in the multivariable anal-
yses were: maternal age, age at which full-time education 
was completed, maternal BMI, partner’s smoking status, 
infant birth weight, gestational age at birth and study arm 
(NRT or placebo). Confounder selection was done using 
the change-in-estimate criteria,19 and any covariate which 
changed the effect size of the univariate exposure-out-
come model by 10% was considered an important 
confounder and included in the fully-adjusted model. 
All analyses were performed using Stata V.14. Significant 
associations were defined at the p≤0.05 significance level.
Patient and public involvement
The original SNAP study had a patient and public involve-
ment (PPI) representative who provided PPI insights for 
the Trial Steering Committee.
results
From 1050 pregnant smokers enrolled in the SNAP trial, 
there were 12 women with twin pregnancies, 14 partici-
pants who had foetal deaths, four lost to follow-up and 10 
who withdrew consent. Of 1010 women with singleton live 
births, data on developmental impairment was available 
for 884 infants. Analyses therefore included maternal and 
2 year records of these 884 infants (figure 1). The self-re-
ported median (IQR) number of daily cigarettes smoked 
by women prior to pregnancy was 19 (10 to 60). At the 
time of recruitment into the study, the reported median 
(IQR) number of cigarettes smoked daily in pregnancy 
was 15 (10 to 20). Of the infants born to participants in 
the study, 52% were males and less than 10% had low 
birth weight. Developmental impairment was present in 
12.7% of these children (n=112).
Study participants and singleton infants with 2 year 
outcome data had similar baseline characteristics to 
participants reported in the full trial cohort.15 Aside 
from the fact that participants who were lost to follow-up 
had higher mean index of multiple deprivation scores 
implying that they lived in more deprived areas than 
participants who had data up to 2 years, there were only 
minor differences in the baseline characteristics between 
the participants with 2 year data and those who were lost 
to follow-up.15
Maternal and infant characteristics
The baseline characteristics of the women and chil-
dren included in the analyses were found to be similar 
in participants randomised to the NRT or placebo study 
arm (presented in table 1). The majority of participants 
included in the study (72.4%) were less than 30 years old; 
the median BMI (IQR) at randomisation into the study 
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was 25.9 (22.2 to 30.7). The average age of leaving full-
time education was 16.3 years. We used the ‘Heaviness 
of Smoking Index’ as a measure of the level of maternal 
nicotine dependence and 65% of women in the study 
had low levels of nicotine dependence prior to being 
recruited in the study. More than two-thirds of the study 
participants had partners who smoked (67.9%). Overall, 
18% of women were validated as abstinent from smoking 
at some point during pregnancy (measured 1 month after 
their target quit date) and 8.9% remained abstinent at 
the latter stages of pregnancy until delivery. There was 
a statistically significant difference in smoking cessation 
outcomes between participants in the NRT and placebo 
arms at the 1 month follow-up but not at delivery.
Analyses of the associations between different measures 
of maternal tobacco smoke exposure and infant develop-
mental impairment found no statistically significant rela-
tionship between maternal smoking exposure and infant 
developmental impairment at age 2 (table 2). The ORs 
for developmental impairment in infants of mothers with 
validated smoking cessation at some point during preg-
nancy (measured at the 1 month follow-up) and in infants 
of mothers with validation cessation at delivery, were 0.99 
(95% CI 0.59 to 1.66) and 1.55 (95% CI 0.84 to 2.87), 
respectively. Adjustment for maternal and infant baseline 
characteristics and covariates did not significantly alter 
the association between maternal smoking and infant 
development. Table 2 shows the unadjusted ORs with 
the different measures of cigarette smoke exposure, as 
well as the ORs adjusted by maternal and infant baseline 
characteristics.
DIsCussIOn
summary of principal findings
We found no associations between maternal smoking 
status at different points during pregnancy and infants’ 
developmental impairment at 2 years. Consequently, 
there is no evidence to support the hypothesis that the 
better infant development observed within infants born 
to women who were randomised to NRT in the SNAP 
trial resulted from smoking cessation induced by nicotine 
patch use.
strengths and limitations
Data for this study are from the largest randomised 
controlled trial of NRT in pregnancy in which partici-
pants, healthcare and research staff were masked to treat-
ment allocation.14 Follow-up and outcome ascertainment 
rates were high and there were only minor differences in 
characteristics of participants lost to follow-up and those 
remaining in the study at 2 years.15 It remains the only 
trial of a smoking cessation intervention in pregnancy 
to monitor infant outcomes; as such it is the only source 
of data which could be used to investigate the study 
hypothesis.
The ASQ-3 is a well-validated screening tool which has 
a sensitivity of 100% and specificity of 93% for detecting 
severe developmental delay at 24 months20. While some 
study infants may have been falsely identified as devel-
opmentally impaired, there is no reason to believe that 
such ASQ-3 false-positives would have occurred more 
frequently in infants of mothers who smoked in preg-
nancy. While developmental impairment was assessed in 
some infants using the participant questionnaire, others 
Figure 1 Flow diagram of study participants. Participants with twin pregnancies (n=12), foetal deaths (n=14), loss to follow-up 
(n=4) and those who withdrew consent (n=10) were excluded from the study analyses. Among participants with singleton live 
births, there were no data on 2 year infant outcomes for 126 participants, so these participants were also excluded from the 
analyses. SNAP, smoking, nicotine and pregnancy. 
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had the health professional questionnaire as the main 
source of data on impairment. Although this consequently 
implies a non-standardised assessment of the outcome 
in all infants, findings from the main study had shown 
that the proportion of participants assessed with either 
the PQ2 or the HPQ were similar in the treatment and 
placebo arms. Also, there were similarities in the baseline 
characteristics and birth outcomes of participants who 
Table 1 Maternal and infant characteristics, by study arm (n=884)




  Maternal age (years) at pregnancy
   <20 72 (16.25) 64 (14.51)
   20–24 142 (32.05) 150 (34.01)
   25–29 n (%) 110 (24.83) 102 (23.13) 0.275
   30–34 64 (14.45) 84 (19.05)
   35–39 44 (9.93) 30 (6.80)
   >40 11 (2.48) 11 (2.49)
  Maternal BMI (kg/m2) (n=847) Median (IQR) 25.71 (22.2–30.7) 26.32 (22.5–30.8) 0.042
  Index of multiple deprivation score Mean (SD) 32.11 (16.83) 32.29 (16.84) 0.754
  Maternal age (years) of leaving full-time education 
(n=872)
Mean (SD) 16.17 (1.36) 16.32 (1.70) 0.95
  Partner’s smoking status
   Non-smoker 108 (24.38) 106 (24.04) 0.962
   Smoker n (%) 301 (67.95) 299 (67.80)
   No data on partner’s smoking status 34 (7.67) 36 (8.16)
  Heaviness of smoking index at study 
randomisation
n (%)
   Low index (0–3) 284 (64.11) 292 (66.21) 0.511
   High index (4–6) 159 (35.89) 149 (33.79)
  Daily number of cigarettes smoked at study 
randomisation
Median (IQR) 13 (10–20) 15 (10-20) 0.799
  Smoking cessation measured during pregnancy (at 
1 month follow-up)
n (%)
   Did not cease smoking 341 (76.98) 384 (87.07) <0.0001
   Ceased smoking 102 (23.02) 57 (12.93)
  Maternal smoking cessation measured at time of 
delivery
n (%)
   Did not cease smoking 397 (89.62) 408 (92.52) 0.131
   Ceased smoking 46 (10.38) 33 (7.48)
Infant characteristics
  Infant sex
   Female n (%) 217 (48.98) 205 (46.49) 0.457
   Male 226 (51.02) 236 (53.51)
  Birth weight
   <2.5kg 48 (10.84) 37 (8.39)
   2.5–3.0kg n (%) 111 (25.06) 104 (23.58) 0.534
   3.0–3.5kg 161 (36.34) 174 (39.46)
   >3.5kg 123 (27.77) 126 (28.57)
  Gestational age at birth (weeks) Median (IQR) 39.5 (2.1) 39.5 (2.2)
BMI, Body Mass Index; NRT, nicotine replacement therapy. 
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returned the PQ2 and those for whom the HPQs were 
completed.
Although we adjusted for some potentially confounding 
factors which are known to be associated with infant 
development such as maternal socioeconomic status,21 
maternal education,22 low birth weight,23 maternal expo-
sure to passive smoking24 and maternal obesity,25 we were 
unable to adjust for those on which we had no data, such 
as maternal nutrition,26 depressive illness,27 stress and 
anxiety28 and alcohol consumption29 which could also 
potentially influence infant development but which were 
not measured in the SNAP trial. There remains therefore, 
the potential for residual confounding.
We undertook secondary analyses of randomised 
controlled trial data and the original sample size was 
intended to have sufficient power only for detecting 
differences in validated smoking cessation rates at the 
end of pregnancy. Analyses presented here may not have 
sufficient power to demonstrate associations between 
smoking and infant development; however, one would 
expect to find one or more such associations if, the rela-
tionship between NRT use and infant development which 
was demonstrated within the same data, were principally 
explained by smoking cessation caused by NRT.
There may have been some misattribution of smoking 
status. Measures of smoking status used were biochemi-
cally-validated at two different time points in pregnancy. 
Validation with carbon monoxide at the earlier time 
point could only eliminate smoking within the previous 
24 hours30; and at delivery, with saliva could only do so 
for the previous 7 days.17 Consequently, some participants 
may have relapsed or smoked occasionally between these 
times31; however we believe it is reasonable to assume 
that women who were validated as not smoking both at 
the end of pregnancy and at 1 month after randomisa-
tion would have lower overall tobacco smoke exposure 
than those who were not. As recruitment into the study 
occurred between 12 and 24 weeks gestation, the timing 
of smoking status measurements in relation to gestation 
will have differed between participants but there is no 
evidence that smoking is more or less harmful at any point 
in pregnancy. Although these were the best available data 
for analyses, the assumptions outlined above need to be 
considered when interpreting study findings.
As most trial participants continued to smoke, analyses 
might have been more illuminating if data on the inten-
sity of women’s smoking during pregnancy had been 
available. For example, if exhaled CO measurements or 
numbers of cigarettes smoked daily in pregnancy had 
been available for non-abstinent trial participants, these 
data could have been used to investigate whether smoking 
intensity in pregnancy was associated infant development. 
Increasing smoking intensity, reflected by exhaled CO 
levels, is associated with reduced infant birth weights,32 so 
an association with development seems possible.
Our analyses did not incorporate postnatal environ-
mental cigarette smoke exposure which may have an 
independent influence on infant development.33 We 
know that there is continued maturation of the connec-
tions between brain regions after birth, with intense brain 
white matter myelination in the first postnatal months 
which becomes progressively less rapid through toddler-
hood until young adulthood.34 Additionally, postnatal 
exposure to environmental tobacco is associated with 
emotional and conduct behavioural problems in school 
aged children35 and so may have an aetiological role in 
infant developmental impairment. As maternal prenatal 
and postnatal smoking are strongly correlated, this would 
increase the likelihood of finding associations between 
smoking in pregnancy and infant development; as none 
were found there is no suggestion of a large impact on 
findings. Nonetheless, there is a need to account for envi-
ronmental cigarette smoke exposure in future studies.
Comparison with literature
As this is an original analysis in a unique trial database 
there is very little literature with which study findings 
can be compared. Previous observational studies have 
found prenatal tobacco exposure to be associated with 
offspring adverse consequences including behavioural36 
and hyperactivity37 38 problems, language and reading 
deficits,37 conduct disorders,39 newborn basic perceptual 
skills40 and intellectual impairment in childhood41 and 
later life.42 However, other studies which adjusted for 
Table 2 Multivariate models of the association between maternal tobacco smoke exposure in pregnancy and child 
developmental impairment at 2 years (analyses restricted to 884 mothers with measures of infant 2 year developmental 
outcome)
ORs (95% CI) for developmental 
impairment at age 2
Unadjusted Adjusted*
Daily number of cigarettes smoked at study randomisation 1.01 (0.98 to 1.04) 1.00 (0.97 to 1.03)
Maternal heaviness of smoking index at study randomisation (high vs low) 1.30 (0.87 to 1.95) 1.26 (0.84 to 1.90)
Maternal smoking cessation in pregnancy (measured 1 month after randomisation) 0.99 (0.59 to 1.66) 1.03 (0.61 to 1.75)
Maternal abstinence from smoking during latter stages of pregnancy (y/n) 1.55 (0.84 to 2.87) 1.53 (0.82 to 2.87)
*Adjusted for maternal age, gestational age at birth and infant birth weight.
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potentially confounding factors such as maternal educa-
tion43 44 and parental socioeconomic status45 have not. 
Consistent with these latter studies, our findings found no 
evidence that the improved developmental outcomes in 
infants of pregnant smokers who used NRT in the SNAP 
trial15 were explained by smoking cessation. As preclinical 
studies show that nicotine is neurotoxic and can adversely 
affect the developing central nervous system,11 12 it seems 
unlikely that these better outcomes are due to a direct 
protective effect of NRT on the developing foetus. Also, 
compliance rates in the NRT patch and placebo study 
arms were low in the SNAP trial (7.2% and 2.8% compli-
ance, respectively, at 1 month). Perhaps, it is possible that 
nicotine used in pregnancy has no impact on infants’ 
developmental outcomes and the apparently protective 
effect of NRT on developmental outcomes observed in 
the SNAP trial occurred by chance.
COnClusIOn
We found no evidence that the better 2 year developmental 
outcomes in offspring of pregnant women randomised to 
NRT patch use in the SNAP trial was due to the smoking 
cessation caused by NRT. Future research which takes 
account of women’s intensity of smoking in pregnancy 
as well as important maternal confounders and postnatal 
exposures, is needed to investigate how NRT use in preg-
nancy may exert this effect on infant development.
Acknowledgements We gratefully acknowledge the SNAP trial team members. In 
addition to listed authors, the complete trial team includes: Investigators: Kim Watts, 
Jim Thornton, Jo Leonardi-Bee, John Britton, Paul Aveyard, Michael Coughtrie, 
Christine Godfrey, Clare Mannion and Neil Marlow. Research staff: Janet Brown, 
Yvette Davis, Anne Dickinson, Caroline Dixon, Fiona Holloway, Joanne Lakin, Jayne 
Platts, Farzana Rashid, Amanda Redford, Cara Taylor. Principal investigators (in 
recruiting centres): Jonathan Allsop, Simon Cunningham, Karen Glass, Vince Hall, 
Khaled Ismail, Margaret Ramsay. Midwife leads (in recruiting centres): Sheena 
Appleby. Denise Bailey, Linda Gustard, Emma Haworth, Grace Hopps, Amanda 
Lindley, Chris Kettle, Colleen Pearce, Dymphna Sexton-Bradshaw, Julia Savage, 
Sandra Smith, Sheila Taylor, Alison Witham. Primary Care Trust & NHS Stop 
Smoking Services’ Staff: Barbara Brady, Michelle Battlemuch, Wendy Dudley, 
Rochelle Edwards, Lorraine Frith, Indu Hari, Catriona Holden, Linda Hoskyns, Paul 
Jackson, Giri Rajaratnam, Deborah Richardson, Lucy Wade, Maureen Whittaker. 
QMC Pharmacy: Bernie Cook, Sheila Hodgson (Lead Pharmacist), Lisa Humphries, 
Bernie Sanders (Qualified Person). University of Nottingham Clinical Trials Unit: Dan 
Simpkins. University of Dundee: Sheila Sharp.
Contributors BI had full access to all of the data in the study and takes 
responsibility for the integrity of the data and the accuracy of the analyses. BI 
also wrote the first draft of the manuscript. LRV contributed to the initial stages of 
data organisation, study concept and design and proofread and approved the full 
manuscript prior to submission. TC contributed to the study hypothesis and design, 
data interpretation and analyses, assisted with writing up the ‘introduction’ section 
and proofread and approved the final manuscript prior to submission. JT, SL and SC 
contributed to the data interpretation and analyses of this study as well as revision 
of the manuscript prior to submission.
Funding This trial was supported by a grant from the NIHR HTA Programme 
(project number 06/07/01). BI’s clinical academic lectureship is fully funded by 
the NIHR. TC, LV, SC and, SL and TC are members of the UK Centre for Tobacco 
and Alcohol Studies (UKCTAS). TC, LV, SC and JT are members of the NIHR School 
for Primary Care Research. Professor Coleman is a National Institute for Health 
Research Senior Investigator. 
Disclaimer Views and opinions expressed are those of the authors and do not 
necessarily reflect those of the National Institute for Health Research (NIHR) Health 
Technology Assessment (HTA) Programme, the NIHR, the National Health Service 
(NHS) or the English Department of Health.
Competing interests None declared.
Patient consent for publication Not required.
ethics approval National research ethical approval for the SNAP trial was granted 
by Oxfordshire Research Ethics Committee A, and additional local approvals for 
each recruitment centre and Clinical Trial Authorisation (CTA) approval was from the 
MHRA (CTA number: 03057/0002/001-0001). All participants gave written informed 
consent, including access to medical records for maintaining contact and for the 
follow-up of their child’s health status.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement This study analysed data from the smoking and nicotine 
in pregnancy (SNAP) trial. All requests for this data should be directed to the snap 
trial team members. Trial participants did not give consent for data sharing but the 
data are anonymised and risk of identification is low.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
reFerenCes
 1. Smoking and the Young. A report of a working party of the Royal 
College of Physicians. London: RCP, 1992.
 2. Mohsin M, Bauman AE. Socio-demographic factors associated with 
smoking and smoking cessation among 426,344 pregnant women in 
New South Wales, Australia. BMC Public Health 2005;5:138.
 3. Egebjerg Jensen K, Jensen A, Nøhr B, et al. Do pregnant women still 
smoke? A study of smoking patterns among 261,029 primiparous 
women in Denmark 1997-2005. Acta Obstet Gynecol Scand 
2008;87:760–7.
 4. Centers for Disease Control and Prevention (CDC). Smoking during 
pregnancy-United States, 1990-2002. MMWR Morb Mortal Wkly Rep 
2004;53:4.
 5. McAndrew F, Thompson J, Fellows L, et al. Infant Feeding Survey 
2010: Health and Social Care Information Centre. 2012.
 6. Oncken CA, Dietz PM, Tong VT, et al. Prenatal tobacco prevention 
and cessation interventions for women in low- and middle-income 
countries. Acta Obstet Gynecol Scand 2010;89:442–53.
 7. World Health Organization. Report on the Global Tobacco Epidemic 
2008—the mpower package. Geneva: World Health Organization, 
2008.
 8. Chamberlain C, O'Mara-Eves A, Oliver S, et al. Psychosocial 
interventions for supporting women to stop smoking in pregnancy. 
Cochrane Database Syst Rev 2013;10:CD001055.
 9. Stead LF, Perera R, Bullen C, et al. Nicotine replacement 
therapy for smoking cessation. Cochrane Database Syst Rev 
2012;11:CD000146.
 10. Dhalwani NN, Szatkowski L, Coleman T, et al. Prescribing of nicotine 
replacement therapy in and around pregnancy: a population-based 
study using primary care data. Br J Gen Pract 2014;64:e554–60.
 11. Dempsey DA, Benowitz NL. Risks and benefits of nicotine to aid 
smoking cessation in pregnancy. Drug Saf 2001;24:277–322.
 12. Benowitz N, Dempsey D. Pharmacotherapy for smoking cessation 
during pregnancy. Nicotine Tob Res 2004;6(Suppl 2):S189–202.
 13. Benowitz NL, Dempsey DA, Goldenberg RL, et al. The use of 
pharmacotherapies for smoking cessation during pregnancy. Tob 
Control 2000;9(Suppl 3):III91–4.
 14. Coleman T, Cooper S, Thornton JG, et al. A randomized trial of 
nicotine-replacement therapy patches in pregnancy. N Engl J Med 
2012;366:808–18.
 15. Cooper S, Taggar J, Lewis S, et al. Effect of nicotine patches in 
pregnancy on infant and maternal outcomes at 2 years: follow-up 
from the randomised, double-blind, placebo-controlled SNAP trial. 
Lancet Respir Med 2014;2:728–37.
 16. Heatherton TF, Kozlowski LT, Frecker RC, et al. Measuring the 
heaviness of smoking: using self-reported time to the first cigarette 
of the day and number of cigarettes smoked per day. Br J Addict 
1989;84:791–9.
 17. Montalto NJ, Wells WO. Validation of self-reported smoking status 
using saliva cotinine: a rapid semiquantitative dipstick method. 
Cancer Epidemiol Biomarkers Prev 2007;16:1858-62.
 o
n




pen: first published as 10.1136/bmjopen-2018-024923 on 11 July 2019. Downloaded from 
8 Iyen B, et al. BMJ Open 2019;9:e024923. doi:10.1136/bmjopen-2018-024923
Open access 
 18. Protocol for the SNAP (Smoking Nicotine and Pregnancy) Trial Final 
version 70. 2009.
 19. Lee PH. Is a cutoff of 10% appropriate for the change-in-estimate 
criterion of confounder identification? J Epidemiol 2014;24:161–7.
 20. Gollenberg AL, Lynch CD, Jackson LW, et al. Concurrent validity of 
the parent-completed Ages and Stages Questionnaires, 2nd Ed. with 
the Bayley Scales of Infant Development II in a low-risk sample. Child 
Care Health Dev 2010;36:485–90.
 21. Ronfani L, Vecchi Brumatti L, Mariuz M, et al. The Complex 
Interaction between Home Environment, Socioeconomic Status, 
Maternal IQ and Early Child Neurocognitive Development: A 
Multivariate Analysis of Data Collected in a Newborn Cohort Study. 
PLoS One 2015;10:e0127052.
 22. Carneiro P, Meghir C, Parey M. Maternal education, home 
environments, and the development of children and adolescents. 
Journal of the European Economic Association 2013;11:123–60.
 23. Stein RE, Siegel MJ, Bauman LJ. Are children of moderately low 
birth weight at increased risk for poor health? A new look at an old 
question. Pediatrics 2006;118:217–23.
 24. Jorge JG, Botelho C, Silva AM, et al. Influence of passive smoking on 
learning in elementary school. J Pediatr 2016;92:260–7.
 25. Wylie A, Sundaram R, Kus C, et al. Maternal prepregnancy obesity 
and achievement of infant motor developmental milestones in the 
upstate KIDS study. Obesity 2015;23:907–13.
 26. Marques AH, O'Connor TG, Roth C, et al. The influence of maternal 
prenatal and early childhood nutrition and maternal prenatal stress 
on offspring immune system development and neurodevelopmental 
disorders. Front Neurosci 2013;7.
 27. Ibanez G, Bernard JY, Rondet C, et al. Effects of Antenatal Maternal 
Depression and Anxiety on Children's Early Cognitive Development: 
A Prospective Cohort Study. PLoS One 2015;10:e0135849.
 28. Tarabulsy GM, Pearson J, Vaillancourt-Morel MP, et al. Meta-analytic 
findings of the relation between maternal prenatal stress and anxiety 
and child cognitive outcome. J Dev Behav Pediatr 2014;35:38–43.
 29. Knudsen AK, Skogen JC, Ystrom E, et al. Maternal pre-pregnancy 
risk drinking and toddler behavior problems: the Norwegian 
Mother and Child Cohort Study. Eur Child Adolesc Psychiatry 
2014;23:901–11.
 30. Secker-Walker RH, Vacek PM, Flynn BS, et al. Exhaled carbon 
monoxide and urinary cotinine as measures of smoking in pregnancy. 
Addict Behav 1997;22:671–84.
 31. Parazzini F, Davoli E, Rabaiotti M, et al. Validity of self-reported 
smoking habits in pregnancy: a saliva cotinine analysis. Acta Obstet 
Gynecol Scand 1996;75:352–4.
 32. Reynolds CME, Egan B, Kennedy RA, et al. The implications of high 
carbon monoxide levels in early pregnancy for neonatal outcomes. 
Eur J Obstet Gynecol Reprod Biol 2019;233:6–11.
 33. Yolton K, Dietrich K, Auinger P, et al. Exposure to environmental 
tobacco smoke and cognitive abilities among U.S. children and 
adolescents. Environ Health Perspect 2005;113:98–103.
 34. Dubois J, Dehaene-Lambertz G, Kulikova S, et al. The early 
development of brain white matter: a review of imaging studies in 
fetuses, newborns and infants. Neuroscience 2014;276:48–71.
 35. Chastang J, Baïz N, Cadwallader JS, et al. Postnatal Environmental 
Tobacco Smoke Exposure Related to Behavioral Problems in 
Children. PLoS One 2015;10.
 36. Carter S, Paterson J, Gao W, et al. Maternal smoking during 
pregnancy and behaviour problems in a birth cohort of 2-year-old 
Pacific children in New Zealand. Early Hum Dev 2008;84:59–66.
 37. Naeye RL, Peters EC. Mental development of children whose 
mothers smoked during pregnancy. Obstet Gynecol 1984;64:601–7.
 38. Langley K, Holmans PA, van den Bree MB, et al. Effects of low birth 
weight, maternal smoking in pregnancy and social class on the 
phenotypic manifestation of Attention Deficit Hyperactivity Disorder 
and associated antisocial behaviour: investigation in a clinical 
sample. BMC Psychiatry 2007;7:26.
 39. Wakschlag LS, Lahey BB, Loeber R, et al. Maternal smoking during 
pregnancy and the risk of conduct disorder in boys. Arch Gen 
Psychiatry 1997;54:670–6.
 40. Key AP, Ferguson M, Molfese DL, et al. Smoking during pregnancy 
affects speech-processing ability in newborn infants. Environ Health 
Perspect 2007;115:623–9.
 41. Olds DL, Henderson CR, Tatelbaum R. Intellectual impairment 
in children of women who smoke cigarettes during pregnancy. 
Pediatrics 1994;93:221–7.
 42. Mortensen EL, Michaelsen KF, Sanders SA, et al. A dose-response 
relationship between maternal smoking during late pregnancy and 
adult intelligence in male offspring. Paediatr Perinat Epidemiol 
2005;19:4–11.
 43. Batty GD, Der G, Deary IJ. Effect of maternal smoking during 
pregnancy on offspring's cognitive ability: empirical evidence for 
complete confounding in the US national longitudinal survey of 
youth. Pediatrics 2006;118:943–50.
 44. Breslau N, Paneth N, Lucia VC, et al. Maternal smoking during 
pregnancy and offspring IQ. Int J Epidemiol 2005;34:1047–53.
 45. Roza SJ, Verhulst FC, Jaddoe VW, et al. Maternal smoking during 








pen: first published as 10.1136/bmjopen-2018-024923 on 11 July 2019. Downloaded from 
